Next |
home / stock / nrsn / nrsn message board
Subject | By | Source | When |
---|---|---|---|
If the relationship goes well they might do | McMagyar | investorshub | 06/22/2023 12:14:56 PM |
Just saw its an engagement with bioscam.. Who would | McMagyar | investorshub | 06/22/2023 12:12:56 PM |
$NRSN MomentumIts trading last trade up | THEMASTERS_SON | investorshub | 06/15/2023 7:04:58 PM |
oh yeah news for the day | THEMASTERS_SON | investorshub | 06/15/2023 11:36:18 AM |
$NRSN The gaining | frankyahoo | investorshub | 06/15/2023 6:18:46 AM |
3rd confirmation of good news | McMagyar | investorshub | 06/14/2023 1:51:50 PM |
$NRSN bears are running | $treet $inatra | investorshub | 06/14/2023 7:53:35 AM |
$NRSN Do we have a winner?Turn around time? | THEMASTERS_SON | investorshub | 06/12/2023 7:26:46 AM |
$NRSN Price trading last up | subslover | investorshub | 06/11/2023 2:19:28 AM |
$NRSN just the news we needed | THEMASTERS_SON | investorshub | 06/10/2023 8:17:11 PM |
$NRSN The gaining up | THEMASTERS_SON | investorshub | 06/09/2023 9:49:31 PM |
$NRSN The gaining last trade up | frankyahoo | investorshub | 06/08/2023 9:12:12 PM |
$NRSN Lets go go go go... Up up and away we go. | subslover | investorshub | 06/08/2023 4:14:01 PM |
what do you make of this data? | subslover | investorshub | 06/06/2023 5:44:02 PM |
MomentumIts trading | conix | investorshub | 06/04/2023 9:02:54 PM |
$NRSN Price gaining | crudeoil24 | investorshub | 06/03/2023 7:56:44 PM |
$NRSN what does this mean? | tw0122 | investorshub | 06/03/2023 4:31:07 PM |
$NRSN MomentumIts trading up | subslover | investorshub | 06/01/2023 1:52:14 PM |
The now up | swampboots | investorshub | 05/30/2023 4:35:33 AM |
$NRSN short squeeze signal | 420man | investorshub | 05/27/2023 11:10:35 AM |
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...